SG11201809716VA - T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRII - Google Patents
T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRIIInfo
- Publication number
- SG11201809716VA SG11201809716VA SG11201809716VA SG11201809716VA SG11201809716VA SG 11201809716V A SG11201809716V A SG 11201809716VA SG 11201809716V A SG11201809716V A SG 11201809716VA SG 11201809716V A SG11201809716V A SG 11201809716VA SG 11201809716V A SG11201809716V A SG 11201809716VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- oslo
- chain domain
- recognise
- vei
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 4
- 230000037433 frameshift Effects 0.000 title abstract 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 2
- 230000009258 tissue cross reactivity Effects 0.000 abstract 6
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000012642 immune effector Substances 0.000 abstract 2
- 229940121354 immunomodulator Drugs 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 abstract 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 abstract 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 abstract 1
- 238000007792 addition Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 231100000221 frame shift mutation induction Toxicity 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4225—Growth factors
- A61K40/4229—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4272—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/50—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Developmental Biology & Embryology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1608052.5A GB201608052D0 (en) | 2016-05-09 | 2016-05-09 | T-cell receptors which recognise frameshift mutants of TGF-beta RII |
| PCT/EP2017/061087 WO2017194555A1 (en) | 2016-05-09 | 2017-05-09 | T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRII |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809716VA true SG11201809716VA (en) | 2018-11-29 |
Family
ID=56297359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809716VA SG11201809716VA (en) | 2016-05-09 | 2017-05-09 | T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRII |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190336529A1 (enExample) |
| EP (1) | EP3455249B1 (enExample) |
| JP (1) | JP2019517790A (enExample) |
| KR (1) | KR20190016507A (enExample) |
| CN (1) | CN109328196B (enExample) |
| AU (1) | AU2017261684A1 (enExample) |
| CA (1) | CA3024555A1 (enExample) |
| EA (1) | EA201892217A1 (enExample) |
| GB (1) | GB201608052D0 (enExample) |
| IL (1) | IL262873A (enExample) |
| MX (1) | MX2018013581A (enExample) |
| SG (1) | SG11201809716VA (enExample) |
| WO (1) | WO2017194555A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10724043B2 (en) * | 2016-10-06 | 2020-07-28 | Nantbio, Inc. | Multi-pulse transfection methods and cells |
| US20190358263A1 (en) | 2016-12-07 | 2019-11-28 | Oslo Universitetssykehus Hf | Compositions and Methods for Cell Therapy |
| GB201713078D0 (en) * | 2017-08-15 | 2017-09-27 | Adaptimmune Ltd | T Cell Modification |
| WO2019069125A1 (en) | 2017-10-06 | 2019-04-11 | Oslo Universitetssykehus Hf | CHIMERIC ANTIGEN RECEPTORS |
| AU2019344871B2 (en) | 2018-09-21 | 2025-04-03 | Xlifesc, Ltd. | High affinity T cell receptor for recognizing AFP antigen |
| US20220193137A1 (en) * | 2019-04-04 | 2022-06-23 | Umc Utrecht Holding B.V. | Modified immune receptor constructs |
| GB201907663D0 (en) | 2019-05-30 | 2019-07-17 | Ab Mavatar | Method for diagnosing colorectal cancer |
| AU2021351710A1 (en) * | 2020-10-02 | 2023-06-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
| WO2023050063A1 (zh) * | 2021-09-28 | 2023-04-06 | 溧阳瑅赛生物医药有限公司 | 一种识别hla-a*02:01/e629-38的tcr及其应用 |
| WO2024050399A1 (en) | 2022-09-01 | 2024-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes |
| WO2024263818A2 (en) * | 2023-06-20 | 2024-12-26 | Immunova Therapeutics Llc | Synthetic t cell receptors for enhancing memory (stem) t cells using new transmembranes and signaling domains |
| TW202506712A (zh) * | 2023-06-21 | 2025-02-16 | 大陸商北京可瑞生物科技有限公司 | 經修飾的ｔｃｒ恒定區及其在ｔｃｒ融合蛋白中的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO315238B1 (no) * | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
| FR2779432A1 (fr) * | 1998-06-08 | 1999-12-03 | Transgene Sa | Sequence nucleique du recepteur rii du tgfb, peptide code, et utilisations |
| EP2459593A2 (en) * | 2009-07-29 | 2012-06-06 | Glaxo Group Limited | Anti-tgf-beta receptor type ii single domain antibodies |
| MY171135A (en) * | 2011-06-03 | 2019-09-27 | Xoma Technology Ltd | Antibodies specific for tgf-beta |
| CA2893918C (en) * | 2012-12-06 | 2020-11-24 | Callaghan Innovation Research Limited | Conjugate compounds |
| WO2015169853A1 (en) * | 2014-05-06 | 2015-11-12 | Universitetet I Oslo | Engineered invariant chain molecule for improved mhc class i loading |
| WO2015189267A2 (en) * | 2014-06-10 | 2015-12-17 | Universitetet I Oslo | Engineered invariant chain molecule for improved mhc class i loading |
-
2016
- 2016-05-09 GB GBGB1608052.5A patent/GB201608052D0/en not_active Ceased
-
2017
- 2017-05-09 US US16/099,329 patent/US20190336529A1/en not_active Abandoned
- 2017-05-09 KR KR1020187035676A patent/KR20190016507A/ko not_active Abandoned
- 2017-05-09 SG SG11201809716VA patent/SG11201809716VA/en unknown
- 2017-05-09 JP JP2018559282A patent/JP2019517790A/ja active Pending
- 2017-05-09 AU AU2017261684A patent/AU2017261684A1/en not_active Abandoned
- 2017-05-09 CA CA3024555A patent/CA3024555A1/en active Pending
- 2017-05-09 CN CN201780038176.8A patent/CN109328196B/zh active Active
- 2017-05-09 EP EP17725537.9A patent/EP3455249B1/en active Active
- 2017-05-09 MX MX2018013581A patent/MX2018013581A/es unknown
- 2017-05-09 EA EA201892217A patent/EA201892217A1/ru unknown
- 2017-05-09 WO PCT/EP2017/061087 patent/WO2017194555A1/en not_active Ceased
-
2018
- 2018-11-07 IL IL262873A patent/IL262873A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3455249A1 (en) | 2019-03-20 |
| US20190336529A1 (en) | 2019-11-07 |
| KR20190016507A (ko) | 2019-02-18 |
| IL262873A (en) | 2019-01-31 |
| GB201608052D0 (en) | 2016-06-22 |
| WO2017194555A1 (en) | 2017-11-16 |
| CA3024555A1 (en) | 2017-11-16 |
| AU2017261684A1 (en) | 2018-12-13 |
| EA201892217A1 (ru) | 2019-08-30 |
| CN109328196B (zh) | 2022-11-01 |
| EP3455249B1 (en) | 2023-05-03 |
| MX2018013581A (es) | 2019-07-04 |
| CN109328196A (zh) | 2019-02-12 |
| JP2019517790A (ja) | 2019-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809716VA (en) | T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRII | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201907427YA (en) | Engineered transferrin receptor binding polypeptides | |
| SG11201805268XA (en) | T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201908023YA (en) | T cell receptors and immune therapy using the same against prame positive cancers | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
| SG11201909395TA (en) | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof | |
| SG11201808783XA (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
| SG11201804787UA (en) | Human immunodeficiency virus neutralizing antibodies | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201808797XA (en) | T cell receptors | |
| SG11201907299XA (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
| SG11201907870VA (en) | Compositions and methods for inhibition of lineage specific proteins | |
| SG11201901548SA (en) | Anti-tim-3 antibodies and use thereof | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof |